HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesPruxelutamide
Chemical structure of CAS 1398046-21-3

Pruxelutamide

CAS No.1398046-21-3
MDL No.N/A
MFC24H19F4N5O2S
MW517.50
InChI KeyKCBJGVDOSBKVKP-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1398046-21-3
Product NamePruxelutamide

Biological Targets

AR

Associated Conditions

COVID-19·breast cancer·prostate cancer·severe acute respiratory syndrome
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.

Frontiers in medicine • Vol. 8 • 2021
PMID: 35111791PMC: PMC8802327DOI: 10.3389/fmed.2021.831449

Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.

Cureus • Vol. 13, Issue 12 • 2021
PMID: 34976549PMC: PMC8712234DOI: 10.7759/cureus.20691

Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.

International journal of molecular sciences • Vol. 22, Issue 24 • 2021
PMID: 34948018PMC: PMC8704202DOI: 10.3390/ijms222413222

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.

Frontiers in medicine • Vol. 8 • 2021
PMID: 34350193PMC: PMC8326462DOI: 10.3389/fmed.2021.668698

Documentation

Similar Products